Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 90.45 USD -1.7% Market Closed
Market Cap: 3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+30%
Revenue
Forecast
+21%
Operating Income
Forecast
+55%
Net Income
Forecast
+42%

Wall Street
Price Targets

TMDX Price Targets Summary
Transmedics Group Inc

Wall Street analysts forecast TMDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TMDX is 117.94 USD with a low forecast of 80.8 USD and a high forecast of 187.95 USD.

TMDX Lowest Forecast
Wall Street Target
80.8 USD
11% Downside
TMDX Average Forecast
Wall Street Target
117.94 USD
30% Upside
TMDX Highest Forecast
Wall Street Target
187.95 USD
108% Upside
Lowest
Price Target
80.8 USD
11% Downside
Average
Price Target
117.94 USD
30% Upside
Highest
Price Target
187.95 USD
108% Upside
Transmedics Group Inc Competitors:
Price Targets
CEVI
CellaVision AB
16% Upside
688236
Beijing Chunlizhengda Medical Instruments Co Ltd
24% Upside
EUZ
Eckert & Ziegler Strahlen und Medizintechnik AG
7% Upside
I
041830
InBody Co Ltd
48% Upside
CEVI
CellaVision AB
16% Upside
688236
Beijing Chunlizhengda Medical Instruments Co Ltd
24% Upside
EUZ
Eckert & Ziegler Strahlen und Medizintechnik AG
7% Upside
I
041830
InBody Co Ltd
48% Upside
RMD
Resmed Inc
13% Upside
CLPT
Clearpoint Neuro Inc
83% Upside
TNDM
Tandem Diabetes Care Inc
103% Upside
4543
Terumo Corp
22% Upside

Revenue
Forecast

Revenue Estimate
Transmedics Group Inc

For the last 7 years the compound annual growth rate for Transmedics Group Inc's revenue is 78%. The projected CAGR for the next 3 years is 21%.

78%
Past Growth
21%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Transmedics Group Inc

The compound annual growth rate of Transmedics Group Inc's operating income for the next 3 years is 55%.

N/A
Past Growth
55%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Transmedics Group Inc

The compound annual growth rate of Transmedics Group Inc's net income for the next 3 years is 42%.

N/A
Past Growth
42%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
TMDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TMDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TMDX stock valuation using valuation multiples.
Wall Street Estimates
TMDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TMDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TMDX's stock price target?
Price Target
117.94 USD

According to Wall Street analysts, the average 1-year price target for TMDX is 117.94 USD with a low forecast of 80.8 USD and a high forecast of 187.95 USD.

What is Transmedics Group Inc's Revenue forecast?
Projected CAGR
21%

For the last 7 years the compound annual growth rate for Transmedics Group Inc's revenue is 78%. The projected CAGR for the next 3 years is 21%.

What is Transmedics Group Inc's Operating Income forecast?
Projected CAGR
55%

The compound annual growth rate of Transmedics Group Inc's operating income for the next 3 years is 55%.

What is Transmedics Group Inc's Net Income forecast?
Projected CAGR
42%

The compound annual growth rate of Transmedics Group Inc's net income for the next 3 years is 42%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 251,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.